Long-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipients
Abstract
This article presents a three-year experience with mTOR inhibitors in the schemes of immunosuppressive therapy in patients post liver transplantation.
About the Authors
M. Sh Khubutia
Sklifosovsky Research Institute for Emergency Medicine, Moscow
Russian Federation
Russian Federation
V. E. Sjutkin
Sklifosovsky Research Institute for Emergency Medicine, Moscow
Russian Federation
Russian Federation
N. K. Kuznetsova
Sklifosovsky Research Institute for Emergency Medicine, Moscow
Russian Federation
Russian Federation
S. V. Zhuravel
Sklifosovsky Research Institute for Emergency Medicine, Moscow
Russian Federation
Russian Federation
M. S. Novruzbekov
Sklifosovsky Research Institute for Emergency Medicine, Moscow
Russian Federation
Russian Federation
References
1. Calcineurin inhibitor minimization protocols in liver transplantation / S.A. Farkas [et al.] // Transpl Int. – 2009. – Vol. 22. – N1. – P. 49–60.
2. Fung, J. Rapamycin: friend, foe, or misunderstood? / J. Fung, A. Marcos // Liver Transpl. – 2003. – Vol. 9. – N5. – P. 469–472.
3. A Decade of Experience Using mTor Inhibitors in Liver Transplantation / J. Campsen [et al.] // J Transplant. – 2011. – doi: 10.1155/2011/913094.
4. Chronic renal failure after transplantation of a nonrenal organ / A.O. Ojo [et al.] // N Engl J Med. – 2003. – Vol. 349. – N 10. – P. 931–940.
5. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study / S. Karie-Guigues [et al.] // Liver Transpl. – 2009. – Vol. 15. – N9. – P. 1083–1091.
6. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function / P. De Simone [et al.] // Transpl Int. – 2009. – Vol. 22. – N 3. – P. 279–286.
7. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation / J.M. Martinez et al. // Transplant Proc. – 2010. – P. 42. – N 2. – P. 641–643.
8. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial / M.F. Abdelmalek [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 3. Р – 694–705.
9. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial / P. De Simone [et al.] // Liver Transpl. – 2009. – Vol. 15. – N 10. – P. 1262–1269.
10. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function / M. Masetti [et al.] // Am J Transplant. – 2010. – Vol. 10. – N 10. – P. 2252–2262.
11. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial / P. De Simone [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 11. – P. 3008–3020.
12. A randomized, controlled study to assess the conversion from calcineurininhibitors to everolimus after liver transplantationPROTECT / L. Fischer [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 7. – P. 1855–1865.
13. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results / G. Levy [et al.] // Liver Transpl. – 2006. – Vol. 12. – N 11. – P. 1640–1648.
14. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis / F. Saliba [et al.] // Liver Transpl. – 2011. – Vol. 17. – N 8. – P. 905–913.
Review
For citations:
Khubutia M.Sh., Sjutkin V.E., Kuznetsova N.K., Zhuravel S.V., Novruzbekov M.S. Long-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipients. Transplantologiya. The Russian Journal of Transplantation. 2013;(2):23-27. (In Russ.)
Views:
1572
Email this article 